https://www.ucsf.edu/news/2022/09/423891/lsd-molecules-counter-depression-without-trip Skip to main content University of California San Francisco Give to UCSF Home Search Small screen search [ ] [Search] Choose what type of search to perform (*) All UCSF ( ) UCSF News Center Main navigation * About + Overview + Mission & Values + Our Impact o Achievements o Economic Impact o UCSF in the Community Give to UCSF + History + Facts & Figures o Budget o Inventions & Entrepreneurship o UCSF Fact Sheet Give to UCSF + Administration o Campus Leaders o Chancellor o Executive Vice Chancellor & Provost o Community & Government Relations o Diversity & Outreach o Finance & Administrative Services o Legal Affairs o Office of Communications o University Development & Alumni Relations Give to UCSF + Locations Give to UCSF * Patient Care + Overview + UCSF Medical Center + UCSF Benioff Children's Hospitals + UCSF Dental Center + Langley Porter Psychiatric Hospital and Clinics + Specialty Clinics + Clinical Trials Give to UCSF * Research + Overview + Partnerships + Office of Research + Innovation Ventures + Postdoctoral Scholars Give to UCSF * Education + Overview + Admissions + Schools & Programs o School of Dentistry o School of Medicine o School of Pharmacy o School of Nursing o Graduate Division o Global Health Sciences Give to UCSF + Resources for Students o Academic Calendar o Career Center o Financial Aid o General Catalog o Library o Registrar o Student Success Guide Give to UCSF Give to UCSF * News & Media + UCSF News Center + UCSF Magazine + Campus News + Media Coverage + Resources for Journalists Give to UCSF * Search Give to UCSF Main navigation - Desktop * About Close About menu. About + Overview + Mission & Values + Our Impact Our Impact o Achievements o Economic Impact o UCSF in the Community + History + Facts & Figures Facts & Figures o Budget o Inventions & Entrepreneurship o UCSF Fact Sheet + Administration Administration o Campus Leaders o Chancellor o Executive Vice Chancellor & Provost o Community & Government Relations o Diversity & Outreach o Finance & Administrative Services o Legal Affairs o Office of Communications o University Development & Alumni Relations + Locations * Patient Care Close Patient Care menu. Patient Care + Overview + UCSF Medical Center + UCSF Benioff Children's Hospitals + UCSF Dental Center + Langley Porter Psychiatric Hospital and Clinics + Specialty Clinics + Clinical Trials * Research Close Research menu. Research + Overview + Partnerships + Office of Research + Innovation Ventures + Postdoctoral Scholars * Education Close Education menu. Education + Overview + Admissions + Schools & Programs Schools & Programs o School of Dentistry o School of Medicine o School of Pharmacy o School of Nursing o Graduate Division o Global Health Sciences + Resources for Students Resources for Students o Academic Calendar o Career Center o Financial Aid o General Catalog o Library o Registrar o Student Success Guide * News & Media Close News & Media menu. News & Media + UCSF News Center + UCSF Magazine + Campus News + Media Coverage + Resources for Journalists * Open or Close Search Form search [ ] Choose what type of search to perform (*) All UCSF ( ) UCSF News Center [Search] Special Notice About COVID-19 Learn about UCSF's response to the coronavirus outbreak, important updates on campus safety precautions, and the latest policies and guidance on our COVID-19 resource website. You can also access information from the CDC. Learn more * Research * September 28, 2022 LSD-Like Molecules Counter Depression Without the Trip Designer Molecules Activate Select Pathway of the Psychedelic Receptor 5HT2a * Share on Facebook * Share on Twitter * Share on Reddit * Email this article * Print this article Scientists have designed compounds that hit the same key receptor that LSD activates without causing hallucinations. A single dose produced powerful antidepressant and antianxiety effects in mice that lasted up to two weeks. The study, appearing Sept. 28, 2022, in Nature, may offer a way to develop new kinds of antidepressants that are more effective and have fewer side effects than current medications, which don't work for many patients and must be taken every day. It represents the culmination of half a dozen years of work by a team that began at UC San Francisco, UNC-Chapel Hill and Yale, and later expanded to Duke and Stanford universities. 3D computer model of the 5HT2a receptorThe 5HT2a serotonin receptor, pictured above, is activated by psychedelics and also new designer molecules that may be able to alleviate depression without the psychedelic effects. The compounds were designed to fit into the 5HT2a receptor, which is the main target of psychedelics like LSD and psilocybin mushrooms. The receptor is also activated by serotonin, a naturally occurring hormone that regulates mood, cognition and many other functions in the body. The 5HT2a receptor is thought to play a role in schizophrenia and other psychotic disorders, as well as anxiety and depression, and a host of antipsychotic and antidepressant drugs block its activity. The new molecules activate it, but in a very different way than psychedelics. Recent studies have found that when given in combination with psychotherapy, one or two high doses of psychedelics like psilocybin and MDMA can have significant long-term effects on depression, anxiety and PTSD. It's not known if the trip is essential to the treatment, or if drugs could be developed that alleviate symptoms without it. The current study offers the possibility of disentangling these effects. Although it's been known for several decades that 5HT2a receptors activate different signaling pathways in cells, until now there were no compounds selective enough to see what each pathway did. The scientific team discovered the receptors could set off two different pathways, a hallucinatory pathway and an antidepressant/ antianxiety one. LSD activates the first one more, while the new compounds activate the second one more. The receptors are like antennae. They pick up a chemical signal, and downstream a bunch of things get activated in a cell. Brian Shoichet, PhD "The receptors are like antennae," said Brian Shoichet, PhD, professor of pharmaceutical chemistry in the UCSF School of Pharmacy. "They pick up a chemical signal, and downstream a bunch of things get activated in a cell." Shoichet and others on the team did not set out to find molecules that could be used to make new drugs for depression. Their initial goal was to find a way to screen a type of molecule called a tetrahydropyridine that is difficult to synthesize and therefore has been absent from virtual libraries, although it is common among FDA-approved drugs. But another team member, Bryan Roth, MD, PhD, of UNC-Chapel Hill, thought the molecules might be an interesting way to test the function of the 5HT2b receptor, which he'd been studying along with 5HT2a since the 1980s. "There wasn't really any sense that drugs like psychedelics that activate this receptor would be therapeutic until psilocybin was tried in clinical trials for depression and shown to have this remarkable effect," he said. "That really galvanized our interest, which basically started this collaboration." Roth, the Michael Hooker Distinguished Professor of Pharmacology at the UNC School of Medicine, and some other team members had recently solved the crystal structure of the 5HT2b receptor. They used that structure to model the 5HT2a until Roth's group worked out the crystal structure of 5HT2a. The compounds had been selected from a computational library of 75 million candidates. Jonathan Ellman, PhD, the Eugene Higgins Professor of Chemistry, and professor of pharmacology at Yale, synthesized them. And the UCSF, UNC, Yale team worked for more than a year to optimize them. "The final molecules were 100 times more potent than what we started with," Shoichet said, although they were still not nearly as strong as LSD. "In the animals they are very potent, much more potent than Prozac." The team expanded to test the designer molecules in mice, adding William Wetsel, PhD, who directs the Mouse Behavioral and Neuroendocrine Analysis Core Facility at Duke. His lab looked for head twitch responses that are the tell-tale signs of psychedelic activity in mice. But the mice hardly twitched. Wetsel's lab ran the mice through a battery of tests to see if the molecules could ameliorate symptoms analogous to human anxiety and depression. And they were highly effective. After many years, what had begun as a science experiment arrived at a discovery with great clinical promise. The work was aided by a $27 million grant that Shoichet and Roth received in 2020 from the Defense Advanced Research Projects Agency (DARPA) to develop new psychiatric medicines. The team's next project will be optimizing the compounds, making them selective enough to be used in clinical trials. The approach has been patented by Yale, UNC-Chapel Hill and UCSF and licensed to Onsero, a Canadian startup. A key issue will be making molecules that have no affinity for 5HT2b. Drugs that hit this receptor, like the banned diet drug fen-phen, can cause valvular heart disease when taken chronically. That receptor is also hit by psychedelics, particularly LSD. "We weren't looking for anything therapeutic," Roth said. "After a huge amount of work, we ended up with these very selective compounds." Authors: In addition to Shoichet, other UCSF authors include co-first author Anat Levit Kaplan, Ying Yang and co-senior author John Irwin. A full list of authors is in the paper. Funding: DARPA HR001119S0092 and NIH grants R35GM122473, R35GM122481, NIDA R37-DA045657 and GM71896. Please see the paper for disclosures. Topics * Neurology * Neurosciences * Pharmacy and Pharmacology * Psychiatry Recommended Reading Illustration of branching vasculature * Research * Sep. 29, 2022 UCSF Researchers Discover How Vascular Cells Develop in Prenatal Brain An elderly woman holds the hand of a caregiver while she gets up * Patient Care * Sep. 26, 2022 Life Expectancy Tool May Improve Quality of Life for Patients With Dementia An illustration of a magnifying glass with several bacterium in view of the lense * Research * Sep. 15, 2022 Dozens of Gut Bacteria Associated with Multiple Sclerosis Stay in touch with the latest updates. Subscribe to UCSF News Are you a member of the news media? Visit the Media Center UCSF Footer Logo Follow Us: * Facebook * Twitter * YouTube * Instagram Get Involved * Become a UCSF Advocate * Volunteer at UCSF Medical Center * Start a Fundraiser * Subscribe to UCSF News Resources * A to Z Website List * Accessibility Resources * Administrative Policies * Brand Guidelines * Campus Life Services * Campus Maps * Careers at UCSF * Chancellor * Diversity & Outreach * Emergency Management * Human Resources * Library * People Directory * Police * Shuttle Schedule * UCSF Profiles (c) 2022 The Regents of The University of California * Sitemap * Site Map * Terms of Use * Report an issue with UCSF.edu website